Product Datasheet

Orforglipron hemicalcium hydrate


Catalog No. **BP-00335** · CAS **3008544-96-2** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-11-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
GCGR	**Metabolic Disease; Inflammation/Immunology**

Molecular formula	$C_{48}H_{50}CaF_2N_{10}O_6$
Molecular weight	**941.0490**

STRUCTURE



DESCRIPTION

Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate) represents the hemicalcium hydrate form of the calcium salt of Orforglipron, an orally active agonist targeting the Glucagon-like peptide-1 receptor (GLP-1R). This compound has demonstrated efficacy in mitigating type 2 diabetes.

BIOLOGICAL ACTIVITY

Orforglipron hemicalcium hydrate (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and blood glucose reduction in cynomolgus monkey model[1].
Orforglipron hemicalcium hydrate (0.05-1.35 mg/kg, i.g.) reaches Cmax 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 25 mg/mL

REFERENCES

[1]. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2018056453A1